Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
A number of other research analysts have also recently commented on COLL. Needham & Company LLC restated a “buy” rating on shares of Collegium Pharmaceutical in a report on Tuesday, December 29th. BidaskClub cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, October 22nd. Finally, HC Wainwright upped their price target on shares of Collegium Pharmaceutical from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $28.86.
COLL stock traded down $0.51 during mid-day trading on Monday, reaching $21.18. 347,139 shares of the stock traded hands, compared to its average volume of 479,230. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.01 and a current ratio of 1.08. Collegium Pharmaceutical has a one year low of $13.00 and a one year high of $25.59. The stock has a market capitalization of $732.45 million, a PE ratio of 43.22, a PEG ratio of 0.57 and a beta of 1.27. The business has a 50-day moving average price of $19.21 and a two-hundred day moving average price of $18.77.
Scientists just uncovered a “test tube miracle” that will revolutionize the pot industry. But the media has been strangely silent about it. Don’t let Wall Street insiders step on you again. Every $1,000 stake could turn into $61,770…
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $0.32 EPS for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.58). The company had revenue of $77.40 million during the quarter, compared to the consensus estimate of $77.39 million. Collegium Pharmaceutical had a return on equity of 12.64% and a net margin of 5.71%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.18) earnings per share. On average, equities analysts expect that Collegium Pharmaceutical will post 0.85 earnings per share for the current fiscal year.
In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 7,060 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $20.82, for a total transaction of $146,989.20. Following the completion of the sale, the executive vice president now directly owns 57,531 shares of the company’s stock, valued at $1,197,795.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Alison B. Fleming sold 5,967 shares of the stock in a transaction dated Thursday, December 3rd. The shares were sold at an average price of $19.24, for a total transaction of $114,805.08. Following the sale, the chief technology officer now directly owns 111,419 shares of the company’s stock, valued at $2,143,701.56. The disclosure for this sale can be found here. 8.08% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in COLL. Advisor Group Holdings Inc. lifted its position in shares of Collegium Pharmaceutical by 104.5% during the second quarter. Advisor Group Holdings Inc. now owns 1,395 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 713 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 332.2% during the third quarter. Nisa Investment Advisors LLC now owns 3,112 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 2,392 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in shares of Collegium Pharmaceutical by 58.9% during the third quarter. Great West Life Assurance Co. Can now owns 3,614 shares of the specialty pharmaceutical company’s stock valued at $99,000 after buying an additional 1,340 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Collegium Pharmaceutical by 539.5% during the third quarter. BNP Paribas Arbitrage SA now owns 7,892 shares of the specialty pharmaceutical company’s stock valued at $164,000 after buying an additional 6,658 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Collegium Pharmaceutical during the third quarter valued at about $204,000.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting.
Featured Article: Moving Average Convergence Divergence (MACD)
Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Food Stocks That Are Leading Through Innovation
It might be easy to dismiss food stocks with so many restaurants still struggling to recover from the global pandemic. But food stocks are a broad category that includes not only the way food is consumed but the way it’s made. In 2020, sustainability and a focus on climate change continue to be important trends in this sector.
Another trend to look at is the ability of companies to deliver food to consumers. It’s not surprising that some of the biggest winners in the pandemic are the restaurants that already had a strong digital presence. Consumers’ ability to have a contactless experience from start to finish has been a catalyst for some stocks.
Not surprisingly, those are also the trends that create an opportunity for investors looking to dabble in food stocks. As you look to resetting your portfolio for 2021, it may be time to take a bite out of some of these stocks.
With that in mind, we’ve put together this special presentation that identifies seven food stocks that you should consider adding to your portfolio. In addition to gaining exposure to this sector, some of these stocks present the opportunity for industry-beating gains.
View the “7 Food Stocks That Are Leading Through Innovation”.
